{
  "study_id": "UMIN000002557",
  "study_title": "FOLFIRI plus bevacizumab as second-line therapy in patients with metastatic colorectal cancer after first-line bevacizumab plus oxaliplatin-based therapy: the randomized phase III EAGLE study",
  "table_name": "Table 1",
  "table_title": "Baseline characteristics",
  "description": "Baseline demographic and clinical characteristics of patients with metastatic colorectal cancer randomized to receive FOLFIRI plus either 5 mg/kg or 10 mg/kg of bevacizumab.",
  "footnotes": [
    "Percentages may not add up to 100% because of rounding.",
    "CA19-9, carbohydrate antigen 19-9; CEA, carcinoembryonic antigen; ECOG, Eastern Cooperative Oncology Group; FOLFIRI, 5-fluorouracil/leucovorin plus irinotecan; mFOLFOX6, modified 5-fluorouracil/leucovorin plus oxaliplatin; XELOX, capecitabine plus oxaliplatin.",
    "aData missing for one patient (bevacizumab 5 mg/kg plus FOLFIRI).",
    "bTarget lesions defined using RECIST, version 1.1."
  ],
  "groups": [
    {
      "name": "Bevacizumab 5 mg/kg plus FOLFIRI",
      "n": 181,
      "type": "Intervention"
    },
    {
      "name": "Bevacizumab 10 mg/kg plus FOLFIRI",
      "n": 188,
      "type": "Intervention"
    }
  ],
  "characteristics": [
    {
      "original_label": "Age, years",
      "standardized_name": "Age",
      "unit": "years",
      "category": "Demographics",
      "time_point": "Baseline",
      "is_sub_characteristic": false,
      "group_data": [
        {
          "group_name": "Bevacizumab 5 mg/kg plus FOLFIRI",
          "data_type": "numeric_median_iqr",
          "median": 66.0,
          "iqr_min": 36.0,
          "iqr_max": 84.0,
          "raw_string": "66 (36-84)"
        },
        {
          "group_name": "Bevacizumab 10 mg/kg plus FOLFIRI",
          "data_type": "numeric_median_iqr",
          "median": 65.0,
          "iqr_min": 31.0,
          "iqr_max": 88.0,
          "raw_string": "65 (31-88)"
        }
      ]
    },
    {
      "original_label": "Sex",
      "standardized_name": "Sex",
      "category": "Demographics",
      "time_point": "Baseline",
      "group_data": [
        {
          "group_name": "Bevacizumab 5 mg/kg plus FOLFIRI",
          "data_type": "header",
          "raw_string": "N (%)"
        },
        {
          "group_name": "Bevacizumab 10 mg/kg plus FOLFIRI",
          "data_type": "header",
          "raw_string": "N (%)"
        }
      ]
    },
    {
      "original_label": "Male",
      "standardized_name": "Male",
      "category": "Demographics",
      "time_point": "Baseline",
      "is_sub_characteristic": true,
      "sub_characteristic_of": "Sex",
      "group_data": [
        {
          "group_name": "Bevacizumab 5 mg/kg plus FOLFIRI",
          "data_type": "categorical_count_percentage",
          "count": 102.0,
          "percentage": 56.0,
          "raw_string": "102 (56)"
        },
        {
          "group_name": "Bevacizumab 10 mg/kg plus FOLFIRI",
          "data_type": "categorical_count_percentage",
          "count": 107.0,
          "percentage": 57.0,
          "raw_string": "107 (57)"
        }
      ]
    },
    {
      "original_label": "Female",
      "standardized_name": "Female",
      "category": "Demographics",
      "time_point": "Baseline",
      "is_sub_characteristic": true,
      "sub_characteristic_of": "Sex",
      "group_data": [
        {
          "group_name": "Bevacizumab 5 mg/kg plus FOLFIRI",
          "data_type": "categorical_count_percentage",
          "count": 79.0,
          "percentage": 44.0,
          "raw_string": "79 (44)"
        },
        {
          "group_name": "Bevacizumab 10 mg/kg plus FOLFIRI",
          "data_type": "categorical_count_percentage",
          "count": 81.0,
          "percentage": 43.0,
          "raw_string": "81 (43)"
        }
      ]
    },
    {
      "original_label": "ECOG performance status",
      "standardized_name": "ECOG performance status",
      "category": "Clinical Characteristics",
      "time_point": "Baseline",
      "group_data": [
        {
          "group_name": "Bevacizumab 5 mg/kg plus FOLFIRI",
          "data_type": "header",
          "raw_string": "N (%)"
        },
        {
          "group_name": "Bevacizumab 10 mg/kg plus FOLFIRI",
          "data_type": "header",
          "raw_string": "N (%)"
        }
      ]
    },
    {
      "original_label": "0",
      "standardized_name": "ECOG 0",
      "category": "Clinical Characteristics",
      "time_point": "Baseline",
      "is_sub_characteristic": true,
      "sub_characteristic_of": "ECOG performance status",
      "group_data": [
        {
          "group_name": "Bevacizumab 5 mg/kg plus FOLFIRI",
          "data_type": "categorical_count_percentage",
          "count": 155.0,
          "percentage": 86.0,
          "raw_string": "155 (86)"
        },
        {
          "group_name": "Bevacizumab 10 mg/kg plus FOLFIRI",
          "data_type": "categorical_count_percentage",
          "count": 163.0,
          "percentage": 87.0,
          "raw_string": "163 (87)"
        }
      ]
    },
    {
      "original_label": "1",
      "standardized_name": "ECOG 1",
      "category": "Clinical Characteristics",
      "time_point": "Baseline",
      "is_sub_characteristic": true,
      "sub_characteristic_of": "ECOG performance status",
      "group_data": [
        {
          "group_name": "Bevacizumab 5 mg/kg plus FOLFIRI",
          "data_type": "categorical_count_percentage",
          "count": 26.0,
          "percentage": 14.0,
          "raw_string": "26 (14)"
        },
        {
          "group_name": "Bevacizumab 10 mg/kg plus FOLFIRI",
          "data_type": "categorical_count_percentage",
          "count": 25.0,
          "percentage": 13.0,
          "raw_string": "25 (13)"
        }
      ]
    },
    {
      "original_label": "No. of metastases",
      "standardized_name": "Number of metastases",
      "category": "Disease Characteristics",
      "time_point": "Baseline",
      "group_data": [
        {
          "group_name": "Bevacizumab 5 mg/kg plus FOLFIRI",
          "data_type": "header",
          "raw_string": "N (%)"
        },
        {
          "group_name": "Bevacizumab 10 mg/kg plus FOLFIRI",
          "data_type": "header",
          "raw_string": "N (%)"
        }
      ]
    },
    {
      "original_label": "<2",
      "standardized_name": "Less than 2 metastases",
      "category": "Disease Characteristics",
      "time_point": "Baseline",
      "is_sub_characteristic": true,
      "sub_characteristic_of": "No. of metastases",
      "group_data": [
        {
          "group_name": "Bevacizumab 5 mg/kg plus FOLFIRI",
          "data_type": "categorical_count_percentage",
          "count": 84.0,
          "percentage": 46.0,
          "raw_string": "84 (46)"
        },
        {
          "group_name": "Bevacizumab 10 mg/kg plus FOLFIRI",
          "data_type": "categorical_count_percentage",
          "count": 84.0,
          "percentage": 45.0,
          "raw_string": "84 (45)"
        }
      ]
    },
    {
      "original_label": "≥2",
      "standardized_name": "2 or more metastases",
      "category": "Disease Characteristics",
      "time_point": "Baseline",
      "is_sub_characteristic": true,
      "sub_characteristic_of": "No. of metastases",
      "group_data": [
        {
          "group_name": "Bevacizumab 5 mg/kg plus FOLFIRI",
          "data_type": "categorical_count_percentage",
          "count": 97.0,
          "percentage": 54.0,
          "raw_string": "97 (54)"
        },
        {
          "group_name": "Bevacizumab 10 mg/kg plus FOLFIRI",
          "data_type": "categorical_count_percentage",
          "count": 104.0,
          "percentage": 55.0,
          "raw_string": "104 (55)"
        }
      ]
    },
    {
      "original_label": "Reason for starting second-line treatment",
      "standardized_name": "Reason for starting second-line treatment",
      "category": "Treatment History",
      "time_point": "Baseline",
      "group_data": [
        {
          "group_name": "Bevacizumab 5 mg/kg plus FOLFIRI",
          "data_type": "header",
          "raw_string": "N (%)"
        },
        {
          "group_name": "Bevacizumab 10 mg/kg plus FOLFIRI",
          "data_type": "header",
          "raw_string": "N (%)"
        }
      ]
    },
    {
      "original_label": "Progressive disease",
      "standardized_name": "Progressive disease",
      "category": "Treatment History",
      "time_point": "Baseline",
      "is_sub_characteristic": true,
      "sub_characteristic_of": "Reason for starting second-line treatment",
      "group_data": [
        {
          "group_name": "Bevacizumab 5 mg/kg plus FOLFIRI",
          "data_type": "categorical_count_percentage",
          "count": 154.0,
          "percentage": 85.0,
          "raw_string": "154 (85)"
        },
        {
          "group_name": "Bevacizumab 10 mg/kg plus FOLFIRI",
          "data_type": "categorical_count_percentage",
          "count": 158.0,
          "percentage": 84.0,
          "raw_string": "158 (84)"
        }
      ]
    },
    {
      "original_label": "Toxicity",
      "standardized_name": "Toxicity",
      "category": "Treatment History",
      "time_point": "Baseline",
      "is_sub_characteristic": true,
      "sub_characteristic_of": "Reason for starting second-line treatment",
      "group_data": [
        {
          "group_name": "Bevacizumab 5 mg/kg plus FOLFIRI",
          "data_type": "categorical_count_percentage",
          "count": 27.0,
          "percentage": 15.0,
          "raw_string": "27 (15)"
        },
        {
          "group_name": "Bevacizumab 10 mg/kg plus FOLFIRI",
          "data_type": "categorical_count_percentage",
          "count": 30.0,
          "percentage": 16.0,
          "raw_string": "30 (16)"
        }
      ]
    },
    {
      "original_label": "Time to recurrence after adjuvant therapy",
      "standardized_name": "Time to recurrence after adjuvant therapy",
      "category": "Treatment History",
      "time_point": "Baseline",
      "group_data": [
        {
          "group_name": "Bevacizumab 5 mg/kg plus FOLFIRI",
          "data_type": "header",
          "raw_string": "N (%)"
        },
        {
          "group_name": "Bevacizumab 10 mg/kg plus FOLFIRI",
          "data_type": "header",
          "raw_string": "N (%)"
        }
      ]
    },
    {
      "original_label": "≤6 months",
      "standardized_name": "≤6 months",
      "category": "Treatment History",
      "time_point": "Baseline",
      "is_sub_characteristic": true,
      "sub_characteristic_of": "Time to recurrence after adjuvant therapy",
      "group_data": [
        {
          "group_name": "Bevacizumab 5 mg/kg plus FOLFIRI",
          "data_type": "categorical_count_percentage",
          "count": 23.0,
          "percentage": 13.0,
          "raw_string": "23 (13)"
        },
        {
          "group_name": "Bevacizumab 10 mg/kg plus FOLFIRI",
          "data_type": "categorical_count_percentage",
          "count": 25.0,
          "percentage": 13.0,
          "raw_string": "25 (13)"
        }
      ]
    },
    {
      "original_label": ">6 months",
      "standardized_name": ">6 months",
      "category": "Treatment History",
      "time_point": "Baseline",
      "is_sub_characteristic": true,
      "sub_characteristic_of": "Time to recurrence after adjuvant therapy",
      "group_data": [
        {
          "group_name": "Bevacizumab 5 mg/kg plus FOLFIRI",
          "data_type": "categorical_count_percentage",
          "count": 158.0,
          "percentage": 87.0,
          "raw_string": "158 (87)"
        },
        {
          "group_name": "Bevacizumab 10 mg/kg plus FOLFIRI",
          "data_type": "categorical_count_percentage",
          "count": 163.0,
          "percentage": 87.0,
          "raw_string": "163 (87)"
        }
      ]
    },
    {
      "original_label": "Primary cancer",
      "standardized_name": "Primary cancer location",
      "category": "Disease Characteristics",
      "time_point": "Baseline",
      "group_data": [
        {
          "group_name": "Bevacizumab 5 mg/kg plus FOLFIRI",
          "data_type": "header",
          "raw_string": "N (%)"
        },
        {
          "group_name": "Bevacizumab 10 mg/kg plus FOLFIRI",
          "data_type": "header",
          "raw_string": "N (%)"
        }
      ]
    },
    {
      "original_label": "Colon",
      "standardized_name": "Colon",
      "category": "Disease Characteristics",
      "time_point": "Baseline",
      "is_sub_characteristic": true,
      "sub_characteristic_of": "Primary cancer",
      "group_data": [
        {
          "group_name": "Bevacizumab 5 mg/kg plus FOLFIRI",
          "data_type": "categorical_count_percentage",
          "count": 115.0,
          "percentage": 64.0,
          "raw_string": "115 (64)"
        },
        {
          "group_name": "Bevacizumab 10 mg/kg plus FOLFIRI",
          "data_type": "categorical_count_percentage",
          "count": 104.0,
          "percentage": 55.0,
          "raw_string": "104 (55)"
        }
      ]
    },
    {
      "original_label": "Rectum",
      "standardized_name": "Rectum",
      "category": "Disease Characteristics",
      "time_point": "Baseline",
      "is_sub_characteristic": true,
      "sub_characteristic_of": "Primary cancer",
      "group_data": [
        {
          "group_name": "Bevacizumab 5 mg/kg plus FOLFIRI",
          "data_type": "categorical_count_percentage",
          "count": 66.0,
          "percentage": 37.0,
          "raw_string": "66 (37)"
        },
        {
          "group_name": "Bevacizumab 10 mg/kg plus FOLFIRI",
          "data_type": "categorical_count_percentage",
          "count": 84.0,
          "percentage": 45.0,
          "raw_string": "84 (45)"
        }
      ]
    },
    {
      "original_label": "Cancer type",
      "standardized_name": "Cancer histology",
      "category": "Disease Characteristics",
      "time_point": "Baseline",
      "group_data": [
        {
          "group_name": "Bevacizumab 5 mg/kg plus FOLFIRI",
          "data_type": "header",
          "raw_string": "N (%)"
        },
        {
          "group_name": "Bevacizumab 10 mg/kg plus FOLFIRI",
          "data_type": "header",
          "raw_string": "N (%)"
        }
      ]
    },
    {
      "original_label": "Adenocarcinoma",
      "standardized_name": "Adenocarcinoma",
      "category": "Disease Characteristics",
      "time_point": "Baseline",
      "is_sub_characteristic": true,
      "sub_characteristic_of": "Cancer type",
      "group_data": [
        {
          "group_name": "Bevacizumab 5 mg/kg plus FOLFIRI",
          "data_type": "categorical_count_percentage",
          "count": 168.0,
          "percentage": 93.0,
          "raw_string": "168 (93)"
        },
        {
          "group_name": "Bevacizumab 10 mg/kg plus FOLFIRI",
          "data_type": "categorical_count_percentage",
          "count": 178.0,
          "percentage": 95.0,
          "raw_string": "178 (95)"
        }
      ]
    },
    {
      "original_label": "Other",
      "standardized_name": "Other",
      "category": "Disease Characteristics",
      "time_point": "Baseline",
      "is_sub_characteristic": true,
      "sub_characteristic_of": "Cancer type",
      "group_data": [
        {
          "group_name": "Bevacizumab 5 mg/kg plus FOLFIRI",
          "data_type": "categorical_count_percentage",
          "count": 9.0,
          "percentage": 5.0,
          "raw_string": "9 (5)"
        },
        {
          "group_name": "Bevacizumab 10 mg/kg plus FOLFIRI",
          "data_type": "categorical_count_percentage",
          "count": 7.0,
          "percentage": 4.0,
          "raw_string": "7 (4)"
        }
      ]
    },
    {
      "original_label": "Unknown",
      "standardized_name": "Unknown",
      "category": "Disease Characteristics",
      "time_point": "Baseline",
      "is_sub_characteristic": true,
      "sub_characteristic_of": "Cancer type",
      "group_data": [
        {
          "group_name": "Bevacizumab 5 mg/kg plus FOLFIRI",
          "data_type": "categorical_count_percentage",
          "count": 4.0,
          "percentage": 2.0,
          "raw_string": "4 (2)"
        },
        {
          "group_name": "Bevacizumab 10 mg/kg plus FOLFIRI",
          "data_type": "categorical_count_percentage",
          "count": 3.0,
          "percentage": 2.0,
          "raw_string": "3 (2)"
        }
      ]
    },
    {
      "original_label": "Site of metastases/recurrence",
      "standardized_name": "Site of metastases or recurrence",
      "category": "Disease Characteristics",
      "time_point": "Baseline",
      "group_data": [
        {
          "group_name": "Bevacizumab 5 mg/kg plus FOLFIRI",
          "data_type": "header",
          "raw_string": "N (%)"
        },
        {
          "group_name": "Bevacizumab 10 mg/kg plus FOLFIRI",
          "data_type": "header",
          "raw_string": "N (%)"
        }
      ]
    },
    {
      "original_label": "Liver",
      "standardized_name": "Liver",
      "category": "Disease Characteristics",
      "time_point": "Baseline",
      "is_sub_characteristic": true,
      "sub_characteristic_of": "Site of metastases/recurrence",
      "group_data": [
        {
          "group_name": "Bevacizumab 5 mg/kg plus FOLFIRI",
          "data_type": "categorical_count_percentage",
          "count": 118.0,
          "percentage": 65.0,
          "raw_string": "118 (65)"
        },
        {
          "group_name": "Bevacizumab 10 mg/kg plus FOLFIRI",
          "data_type": "categorical_count_percentage",
          "count": 113.0,
          "percentage": 60.0,
          "raw_string": "113 (60)"
        }
      ]
    },
    {
      "original_label": "Lung",
      "standardized_name": "Lung",
      "category": "Disease Characteristics",
      "time_point": "Baseline",
      "is_sub_characteristic": true,
      "sub_characteristic_of": "Site of metastases/recurrence",
      "group_data": [
        {
          "group_name": "Bevacizumab 5 mg/kg plus FOLFIRI",
          "data_type": "categorical_count_percentage",
          "count": 75.0,
          "percentage": 41.0,
          "raw_string": "75 (41)"
        },
        {
          "group_name": "Bevacizumab 10 mg/kg plus FOLFIRI",
          "data_type": "categorical_count_percentage",
          "count": 88.0,
          "percentage": 47.0,
          "raw_string": "88 (47)"
        }
      ]
    },
    {
      "original_label": "Lymph nodes",
      "standardized_name": "Lymph nodes",
      "category": "Disease Characteristics",
      "time_point": "Baseline",
      "is_sub_characteristic": true,
      "sub_characteristic_of": "Site of metastases/recurrence",
      "group_data": [
        {
          "group_name": "Bevacizumab 5 mg/kg plus FOLFIRI",
          "data_type": "categorical_count_percentage",
          "count": 56.0,
          "percentage": 31.0,
          "raw_string": "56 (31)"
        },
        {
          "group_name": "Bevacizumab 10 mg/kg plus FOLFIRI",
          "data_type": "categorical_count_percentage",
          "count": 61.0,
          "percentage": 32.0,
          "raw_string": "61 (32)"
        }
      ]
    },
    {
      "original_label": "Peritoneum",
      "standardized_name": "Peritoneum",
      "category": "Disease Characteristics",
      "time_point": "Baseline",
      "is_sub_characteristic": true,
      "sub_characteristic_of": "Site of metastases/recurrence",
      "group_data": [
        {
          "group_name": "Bevacizumab 5 mg/kg plus FOLFIRI",
          "data_type": "categorical_count_percentage",
          "count": 35.0,
          "percentage": 19.0,
          "raw_string": "35 (19)"
        },
        {
          "group_name": "Bevacizumab 10 mg/kg plus FOLFIRI",
          "data_type": "categorical_count_percentage",
          "count": 36.0,
          "percentage": 19.0,
          "raw_string": "36 (19)"
        }
      ]
    },
    {
      "original_label": "Othera",
      "standardized_name": "Other",
      "category": "Disease Characteristics",
      "time_point": "Baseline",
      "is_sub_characteristic": true,
      "sub_characteristic_of": "Site of metastases/recurrence",
      "group_data": [
        {
          "group_name": "Bevacizumab 5 mg/kg plus FOLFIRI",
          "data_type": "categorical_count_percentage",
          "count": 25.0,
          "percentage": 14.0,
          "raw_string": "25 (14)",
          "notes": "Data missing for one patient in this group."
        },
        {
          "group_name": "Bevacizumab 10 mg/kg plus FOLFIRI",
          "data_type": "categorical_count_percentage",
          "count": 28.0,
          "percentage": 15.0,
          "raw_string": "28 (15)"
        }
      ]
    },
    {
      "original_label": "First-line chemotherapy regimen",
      "standardized_name": "First-line chemotherapy regimen",
      "category": "Treatment History",
      "time_point": "Baseline",
      "group_data": [
        {
          "group_name": "Bevacizumab 5 mg/kg plus FOLFIRI",
          "data_type": "header",
          "raw_string": "N (%)"
        },
        {
          "group_name": "Bevacizumab 10 mg/kg plus FOLFIRI",
          "data_type": "header",
          "raw_string": "N (%)"
        }
      ]
    },
    {
      "original_label": "mFOLFOX6",
      "standardized_name": "mFOLFOX6",
      "category": "Treatment History",
      "time_point": "Baseline",
      "is_sub_characteristic": true,
      "sub_characteristic_of": "First-line chemotherapy regimen",
      "group_data": [
        {
          "group_name": "Bevacizumab 5 mg/kg plus FOLFIRI",
          "data_type": "categorical_count_percentage",
          "count": 105.0,
          "percentage": 58.0,
          "raw_string": "105 (58)"
        },
        {
          "group_name": "Bevacizumab 10 mg/kg plus FOLFIRI",
          "data_type": "categorical_count_percentage",
          "count": 110.0,
          "percentage": 59.0,
          "raw_string": "110 (59)"
        }
      ]
    },
    {
      "original_label": "XELOX",
      "standardized_name": "XELOX",
      "category": "Treatment History",
      "time_point": "Baseline",
      "is_sub_characteristic": true,
      "sub_characteristic_of": "First-line chemotherapy regimen",
      "group_data": [
        {
          "group_name": "Bevacizumab 5 mg/kg plus FOLFIRI",
          "data_type": "categorical_count_percentage",
          "count": 27.0,
          "percentage": 15.0,
          "raw_string": "27 (15)"
        },
        {
          "group_name": "Bevacizumab 10 mg/kg plus FOLFIRI",
          "data_type": "categorical_count_percentage",
          "count": 36.0,
          "percentage": 19.0,
          "raw_string": "36 (19)"
        }
      ]
    },
    {
      "original_label": "Other",
      "standardized_name": "Other",
      "category": "Treatment History",
      "time_point": "Baseline",
      "is_sub_characteristic": true,
      "sub_characteristic_of": "First-line chemotherapy regimen",
      "group_data": [
        {
          "group_name": "Bevacizumab 5 mg/kg plus FOLFIRI",
          "data_type": "categorical_count_percentage",
          "count": 49.0,
          "percentage": 27.0,
          "raw_string": "49 (27)"
        },
        {
          "group_name": "Bevacizumab 10 mg/kg plus FOLFIRI",
          "data_type": "categorical_count_percentage",
          "count": 42.0,
          "percentage": 22.0,
          "raw_string": "42 (22)"
        }
      ]
    },
    {
      "original_label": "Resection status",
      "standardized_name": "Resection status",
      "category": "Disease Characteristics",
      "time_point": "Baseline",
      "group_data": [
        {
          "group_name": "Bevacizumab 5 mg/kg plus FOLFIRI",
          "data_type": "header",
          "raw_string": "N (%)"
        },
        {
          "group_name": "Bevacizumab 10 mg/kg plus FOLFIRI",
          "data_type": "header",
          "raw_string": "N (%)"
        }
      ]
    },
    {
      "original_label": "Resected",
      "standardized_name": "Resected",
      "category": "Disease Characteristics",
      "time_point": "Baseline",
      "is_sub_characteristic": true,
      "sub_characteristic_of": "Resection status",
      "group_data": [
        {
          "group_name": "Bevacizumab 5 mg/kg plus FOLFIRI",
          "data_type": "categorical_count_percentage",
          "count": 153.0,
          "percentage": 85.0,
          "raw_string": "153 (85)"
        },
        {
          "group_name": "Bevacizumab 10 mg/kg plus FOLFIRI",
          "data_type": "categorical_count_percentage",
          "count": 149.0,
          "percentage": 79.0,
          "raw_string": "149 (79)"
        }
      ]
    },
    {
      "original_label": "Non-resected",
      "standardized_name": "Non-resected",
      "category": "Disease Characteristics",
      "time_point": "Baseline",
      "is_sub_characteristic": true,
      "sub_characteristic_of": "Resection status",
      "group_data": [
        {
          "group_name": "Bevacizumab 5 mg/kg plus FOLFIRI",
          "data_type": "categorical_count_percentage",
          "count": 27.0,
          "percentage": 15.0,
          "raw_string": "27 (15)"
        },
        {
          "group_name": "Bevacizumab 10 mg/kg plus FOLFIRI",
          "data_type": "categorical_count_percentage",
          "count": 39.0,
          "percentage": 21.0,
          "raw_string": "39 (21)"
        }
      ]
    },
    {
      "original_label": "Cycles of first-line oxaliplatin, n",
      "standardized_name": "Cycles of first-line oxaliplatin",
      "unit": "cycles",
      "category": "Treatment History",
      "time_point": "Baseline",
      "group_data": [
        {
          "group_name": "Bevacizumab 5 mg/kg plus FOLFIRI",
          "data_type": "numeric_median_iqr",
          "median": 12.0,
          "iqr_min": 4.0,
          "iqr_max": 33.0,
          "raw_string": "12 (4-33)"
        },
        {
          "group_name": "Bevacizumab 10 mg/kg plus FOLFIRI",
          "data_type": "numeric_median_iqr",
          "median": 12.0,
          "iqr_min": 4.0,
          "iqr_max": 30.0,
          "raw_string": "12 (4-30)"
        }
      ]
    },
    {
      "original_label": "Cycles of first-line bevacizumab, n",
      "standardized_name": "Cycles of first-line bevacizumab",
      "unit": "cycles",
      "category": "Treatment History",
      "time_point": "Baseline",
      "group_data": [
        {
          "group_name": "Bevacizumab 5 mg/kg plus FOLFIRI",
          "data_type": "numeric_median_iqr",
          "median": 15.0,
          "iqr_min": 4.0,
          "iqr_max": 54.0,
          "raw_string": "15 (4-54)"
        },
        {
          "group_name": "Bevacizumab 10 mg/kg plus FOLFIRI",
          "data_type": "numeric_median_iqr",
          "median": 15.0,
          "iqr_min": 4.0,
          "iqr_max": 64.0,
          "raw_string": "15 (4-64)"
        }
      ]
    },
    {
      "original_label": "CEA, ng/ml",
      "standardized_name": "Carcinoembryonic antigen (CEA)",
      "unit": "ng/ml",
      "category": "Biomarkers",
      "time_point": "Baseline",
      "group_data": [
        {
          "group_name": "Bevacizumab 5 mg/kg plus FOLFIRI",
          "data_type": "numeric_median_iqr",
          "median": 23.2,
          "iqr_min": 0.4,
          "iqr_max": 9279.0,
          "raw_string": "23.2 (0.40-9279)",
          "n_for_value": 176
        },
        {
          "group_name": "Bevacizumab 10 mg/kg plus FOLFIRI",
          "data_type": "numeric_median_iqr",
          "median": 18.2,
          "iqr_min": 0.7,
          "iqr_max": 2049.0,
          "raw_string": "18.2 (0.70-2049)",
          "n_for_value": 179
        }
      ]
    },
    {
      "original_label": "CA19-9, ng/ml",
      "standardized_name": "Carbohydrate antigen 19-9 (CA19-9)",
      "unit": "ng/ml",
      "category": "Biomarkers",
      "time_point": "Baseline",
      "group_data": [
        {
          "group_name": "Bevacizumab 5 mg/kg plus FOLFIRI",
          "data_type": "numeric_median_iqr",
          "median": 38.3,
          "iqr_min": 0.6,
          "iqr_max": 48019.0,
          "raw_string": "38.3 (0.60-48019)",
          "n_for_value": 175
        },
        {
          "group_name": "Bevacizumab 10 mg/kg plus FOLFIRI",
          "data_type": "numeric_median_iqr",
          "median": 36.1,
          "iqr_min": 0.1,
          "iqr_max": 50000.0,
          "raw_string": "36.1 (0.10-50 000)",
          "n_for_value": 178
        }
      ]
    },
    {
      "original_label": "Sum of target lesions,b mm",
      "standardized_name": "Sum of target lesions",
      "unit": "mm",
      "category": "Disease Characteristics",
      "time_point": "Baseline",
      "group_data": [
        {
          "group_name": "Bevacizumab 5 mg/kg plus FOLFIRI",
          "data_type": "numeric_median_iqr",
          "median": 50.0,
          "iqr_min": 4.4,
          "iqr_max": 254.0,
          "raw_string": "50.0 (4.40-254)",
          "n_for_value": 181
        },
        {
          "group_name": "Bevacizumab 10 mg/kg plus FOLFIRI",
          "data_type": "numeric_median_iqr",
          "median": 44.4,
          "iqr_min": 10.0,
          "iqr_max": 246.0,
          "raw_string": "44.4 (10-246)",
          "n_for_value": 186
        }
      ]
    }
  ]
}